글로벌 IP 소식
국내외 IP 소식을 제공합니다.
글로벌 IP 소식
국내외 IP 소식을 제공합니다.
에디터 교체 테스트
df sdfsdfsdfsdfdsf sfs dfdfsdfdfsdfsdfsdfsdfsdfsdfsdfawdfasdfasdfasdfsdafdsafdsafdsafasdfasdfdsafasdfadsfadsfasdfadsfadsfdsaf xdgfdfgdfxg sdfsdfsdfdssdfsdf ㅇㄹㄴㅇㄹㄴㅇㄹㄴㅇㄹ 인용구래요 자주쓰는 스톼일~~~ asdfasdfadsf asdfasdf asdfasdfsadf asdfasdfasdf 제목 1입니다. 제목 2입니다. 제목 3입니다. 제목 4입니다. 제목 5입니다. 제목 6입니다. 너무 작네요 d s f
라임프렌즈2024-09-12
ddd
dd
라임프렌즈2024-09-12test
sdfdsfsdfaf dsafdsafadsfasdfadsfadsfdasfasfddsaf
라임프렌즈2024-09-12
- 라이센싱
Samjin Pharmaceuticals Halts Development of Sjogren's Syndrome Treatment SA001 after 10 Years
Samjin Pharmaceuticals has decided to discontinue the clinical development of 'SA001,' a treatment for Sjogren's syndrome. This decision comes approximately 10 years after the company began serious clinical trials. Samjin Pharmaceuticals announced their plan to cease the development of SA001 and redirect their development efforts towards other new drug projects. Initially, SA001 was being developed as an oral treatment for dry eye syndrome, a promising candidate since existing treatments wer...
2024-08-08
- 보도자료
글로벌 IP 소식 등록 1
test
2024-06-26